… This raises concern about the efficacy of the marker to predict the PD-1/PD-L1 inhibitor …
carcinomas only, our results might better reflect actual therapeutic indications for PD-L1 status …

… high PD-L1 expression strongly correlated with shorter overall survival. In our study, two
different anti-PD-L1 … used for head and neck squamous cell carcinoma) were used in 2 different …

… Finally, we show the role of this PD-1/PD-L1 interaction in the TDLN of stage II melanoma …
TDLNs in patients with early disease recurrence are enriched for PD-1/PD-L1 interactions …

… subtypes such as salivary duct carcinomas. In addition, there is no standard treatment with
confirmed efficacy for patients with unresectable primaries, relapses, or distant metastases. …

… 1 (PD-L1). Understanding and evaluating TILs and PD-L1 in breast carcinoma provide …
TILs in the peritumoral area; and TILs around benign ducts and lobules or carcinoma in situ. …

… involved ducts, or when it is not clear, as an area surrounding ducts … As for PD-L1, PD-L1+
immune cells were considered to be … by PD-L1+ immune cells, as previously described [16]. …

… Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison
to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1−). We compared our results …

… /PD-L1 therapy in cutaneous adnexal carcinomas, we aimed here to determine the expression
pattern of PD-L1 in … mammary carcinoma, ductal sweat gland carcinoma, and salivary duct …

… As salivary duct carcinoma also has a very poor … cystic carcinoma and salivary duct carcinoma
to determine whether the application of immune checkpoint inhibitors such as PD-L1, PD-1…

… PD-L1 staining (89%), but 25% of cases were positive for immune cell staining. We observed
that, as in invasive breast cancer, TILs and PD-L1 … ) but not with PD-L1. The TILs score was …